Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 48

Sort by

Sort Order Select

Journal Articles

Overcoming Adaptive Therapy Resistance in AML By Targeting Immune Response Pathways

Blood (2019) 134 (Supplement_1): 3934.

https://doi.org/10.1182/blood-2019-124178

Published: 2019

Journal Articles

Pevonedistat, a Nedd-8 Activating Enzyme Inhibitor, Upregulates NOXA to Increase Effectiveness of Azacitidine and Venetoclax in Preclinical Models of Acute Myelogenous Leukemia

Brianna N Smith, MD MS, Dan Cojocari, PhD BSc, Julie J Purkal, MA, Maria Arrate, MSc, Haley E. Ramsey, PhDMSc, Joel D. Leverson, PhD, Erwin Boghaert, MS, MD, Darren C. Phillips, PhD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 1380.

https://doi.org/10.1182/blood-2019-123068

Published: 2019

Journal Articles

Design and characterization of α1-antitrypsin variants for treatment of contact system–driven thromboinflammation

Steven de Maat, Wariya Sanrattana, Reiner K. Mailer, Naomi M. J. Parr, Martin Hessing, Robert M. Koetsier, Joost C. M. Meijers, Gerard Pasterkamp, Thomas Renné, Coen Maas

Blood (2019) 134 (19): 1658–1669.

https://doi.org/10.1182/blood.2019000481

Published: 2019

Includes: Supplemental data

Journal Articles

A Genome-Wide CRISPR/Cas9 Knockout Screen Identifies BEND3 As a Determinant of Sensitivity to UBA1 Inhibition in Acute Myeloid Leukemia

Samir H Barghout, BSPharm, MSc, Neil MacLean, G. Wei Xu, Geethu Thomas, PhDMSc,BSc, Zachary Blatman, Rose Hurren, BSc, Aaron D Schimmer, MD PhD

Blood (2018) 132 (Supplement 1): 1350.

https://doi.org/10.1182/blood-2018-99-110406

Published: 2018

Journal Articles

Proteometabolomics of Melphalan Resistance in Multiple Myeloma

David C. Koomen, BS, Joy D. Guingab, PhD, Paula S. Oliveira, Bin Fang, PhD, Min Liu, PhD, Eric A. Welsh, PhD, Mark B. Meads, PhD, Tuan Nguyen, Laurel E. Meke, Steven A. Eschrich, PhD, Timothy J. Garrett, PhD, John M. Koomen, PhD, Kenneth H. Shain, MD PhD

Blood (2018) 132 (Supplement 1): 5619.

https://doi.org/10.1182/blood-2018-99-117747

Published: 2018

Journal Articles

Aberrant Cytokine Production in Myelofibrosis Is Not Rectified By Ruxolitinib and Is Differentially Sensitive to Inhibition of JAK/STAT, MAP Kinase, and NFκB Signaling

Daniel A.C. Fisher, PhD, Cathrine Miner, Elizabeth Engle, PhD, Hengrui Hu, Taylor B. Collins, Amy Zhou, MD, Maggie J. Allen, Olga Malkova, Stephen T Oh, MD PhD

Blood (2018) 132 (Supplement 1): 3062.

https://doi.org/10.1182/blood-2018-99-119022

Published: 2018

Journal Articles

Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML

Ronan T. Swords, Steven Coutre, Michael B. Maris, Joshua F. Zeidner, James M. Foran, Jose Cruz, Harry P. Erba, Jesus G. Berdeja, Wayne Tam, Saran Vardhanabhuti, Iwona Pawlikowska-Dobler, Hélène M. Faessel, Ajeeta B. Dash, Farhad Sedarati, Bruce J. Dezube, Douglas V. Faller, Michael R. Savona

Blood (2018) 131 (13): 1415–1424.

https://doi.org/10.1182/blood-2017-09-805895

Published: 2018

Includes: Supplemental data

Journal Articles

Suppression of mTOR Signaling Attenuates Apoptotic Effects Induced By the NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Acute Myeloid Leukemia Cells

Naxin Guo, PhD, Mary Nemer, Subanky Sivagnanalingam, Mitra Azadniv, PhD, Jason H. Mendler, MD PhD, Michael W. Becker, MD, Jane L. Liesveld, MD

Blood (2017) 130 (Supplement 1): 3820.

https://doi.org/10.1182/blood.V130.Suppl_1.3820.3820

Published: 2017

Journal Articles

TAS4464, a Novel, Highly Potent NEDD8-Activating Enzyme Inhibitor Shows Antitumor Activity in Ibrutinib-Insensitive Mantle Cell Lymphoma Via Inactivation of the NF-κB Pathway

Hiromi Muraoka, MS, Chihoko Yoshimura, PhD, Shingo Tsuji, MS, Akihiro Hashimoto, Fumio Nakagawa, Takashi Mizutani, PhD, Shuichi Ohkubo, PhD, Kenichi Matsuo, PhD, Teruhiro Utsugi, PhD, Yoshikazu Iwasawa, PhD

Blood (2017) 130 (Supplement 1): 4103.

https://doi.org/10.1182/blood.V130.Suppl_1.4103.4103

Published: 2017

Journal Articles

TAK-243 Is a Selective UBA1 Inhibitor That Displays Preclinical Activity in Acute Myeloid Leukemia (AML)

Samir H. Barghout, BSPharm, MSc, Parasvi Patel, BSc (Hons), Xiaoming Wang, G. Wei Xu, Simon Kavanagh, Marcela Gronda, MSc, Rose Hurren, BSc, Danny V. Jeyaraju, PhD, Neil MacLean, Marc Hyer, PhD, Allison Berger, PhD, Tary Traore, Michael Sintchak, Michael Milhollen, Mark D. Minden, MD PhD, Razq Hakem, PhD, Aaron D. Schimmer, MDPhD

Blood (2017) 130 (Supplement 1): 814.

https://doi.org/10.1182/blood.V130.Suppl_1.814.814

Published: 2017

Journal Articles

First in Human, Phase I/II Trial of the Bruton's Tyrosine Kinase Inhibitor (BTKi) M7583 in Patients with B Cell Malignancies: Study Design and Initial Outcomes

Wojciech Jurczak, Simon Rule, MD, William Townsend, David Tucker, Martin Dyroff, Barbara Sarholz, Jürgen Scheele, John G. Gribben, MDDSc FMedSci, Pier Luigi Zinzani, MD

Blood (2017) 130 (Supplement 1): 2778.

https://doi.org/10.1182/blood.V130.Suppl_1.2778.2778

Published: 2017

Journal Articles

Altered Expression of Neddylation Pathway Proteins in Myelodysplastic Syndromes

Fatemeh Majidi, MD, Judith Neukirchen, MD, Simon Brille, Iris Fey, BSc., Frank Neumann, MDPhD, Allison Berger, PhD, Ron-Patrick Cadeddu, PhD, Martina Rudelius, MD, Ulrich Germing, MD, Rainer Haas, MD, Norbert Gattermann, MD

Blood (2017) 130 (Supplement 1): 5298.

https://doi.org/10.1182/blood.V130.Suppl_1.5298.5298

Published: 2017

Journal Articles

The Impact of Autophagy on the Progression of the Myelodysplastic Syndromes

Fathima Shahla Vilcassim, MBBchBAO, Ashish Banerjee, PhD, George Grigoriadis, MBBS, PhD BSc

Blood (2016) 128 (22): 3163.

https://doi.org/10.1182/blood.V128.22.3163.3163

Published: 2016

Journal Articles

Inhibition of HDAC5-Mediated p65 Deacetylation Enhances Human Cord Blood Hematopoietic Stem Cell Homing and Engraftment in NSG Mice

Xinxin Huang, PhD, Bin Guo, PhD, Hal E. Broxmeyer, PhD

Blood (2016) 128 (22): 884.

https://doi.org/10.1182/blood.V128.22.884.884

Published: 2016

Journal Articles

Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo

Natalie M. Czuczman, Matthew J. Barth, Juan Gu, Vishala Neppalli, Cory Mavis, Sarah E. Frys, Qiang Hu, Song Liu, Pavel Klener, Petra Vockova, Myron S. Czuczman, Francisco J. Hernandez-Ilizaliturri

Blood (2016) 127 (9): 1128–1137.

https://doi.org/10.1182/blood-2015-04-640920

Published: 2016

Includes: Supplemental data

Journal Articles

The NEDD8 Activating Enzyme Inhibitor Pevonedistat Induces ER Stress/UPR-Mediated Cell Death and Rebalances Homeostasis of Pro- and Anti-Apoptotic Proteins in Favor of Cell Death in Acute Lymphoblastic Leukemia Cells

Gilles M. Leclerc, PhD, Shuhua Zheng, BS, Guy J. Leclerc, PhD, Joanna DeSalvo, BSc, Ronan T. Swords, MDPhDFRCPI FRCPath, Julio C. Barredo, MD

Blood (2015) 126 (23): 1327.

https://doi.org/10.1182/blood.V126.23.1327.1327

Published: 2015

Journal Articles

FAM20c-Mediated Serine 1613 Phosphorylation in the A2 Domain of Von Willebrand Factor Regulates ADAMTS13 Activity and Thrombus Formation

Qi Da, PhD, Jennifer Nolasco, B.S., Tanvir Khatlani, PhD, Fernandez Maria, B,S., Miguel A. Cruz, PhD, K. Vinod Vijayan, PhD

Blood (2015) 126 (23): 236.

https://doi.org/10.1182/blood.V126.23.236.236

Published: 2015

Journal Articles

Immunomodulatory Drugs Are Efficacious Against Primary Effusion Lymphoma By Targeting IKZF1, IRF4 and MYC in a CRBN-Dependent Manner and Are Synergistic with BRD4 Inhibitors

Ramakrishnan Gopalakrishnan, PhD, Hittu Matta, PhD, Bhairavi Tolani, PhD, Timothy Junius Triche, PhD, Preet Chaudhary, MDPhD

Blood (2014) 124 (21): 3109.

https://doi.org/10.1182/blood.V124.21.3109.3109

Published: 2014

Journal Articles

Inhibition of Nuclear Factor Kappa B (NFkB)/Interferon Regulatory Factor 4 (IRF4) Signaling Pathway in Activated B-Cell (ABC) Diffuse Large B-Cell Lymphoma (DLBCL) By Combining MLN4924, a Novel NEDD8 Activating Enzyme Inhibitor (NAE) and Ibrutinib

Pallawi Torka, MD, Francisco J. Hernandez-Ilizaliturri, MD, Sarah Belliotti, B.A., Cory Mavis, MSc, Juan Gu, PhD, Myron S. Czuczman, MD

Blood (2014) 124 (21): 1768.

https://doi.org/10.1182/blood.V124.21.1768.1768

Published: 2014

Journal Articles

Targeting Microenvironment-Mediated NFκb Activation With MLN4924, An Inhibitor Of The Nedd8-Activating Enzyme, In Chronic Lymphocytic Leukemia B Cells

Claire Godbersen, Alan Eastman, Jennifer R. Brown, MD, PhD, Alexey V. Danilov, MD, PhD

Blood (2013) 122 (21): 2875.

https://doi.org/10.1182/blood.V122.21.2875.2875

Published: 2013

NARROW

Overcoming Adaptive Therapy Resistance in AML By Targeting Immune Response Pathways

Pevonedistat, a Nedd-8 Activating Enzyme Inhibitor, Upregulates NOXA to Increase Effectiveness of Azacitidine and Venetoclax in Preclinical Models of Acute Myelogenous Leukemia

Design and characterization of α1-antitrypsin variants for treatment of contact system–driven thromboinflammation

A Genome-Wide CRISPR/Cas9 Knockout Screen Identifies BEND3 As a Determinant of Sensitivity to UBA1 Inhibition in Acute Myeloid Leukemia

Proteometabolomics of Melphalan Resistance in Multiple Myeloma

Aberrant Cytokine Production in Myelofibrosis Is Not Rectified By Ruxolitinib and Is Differentially Sensitive to Inhibition of JAK/STAT, MAP Kinase, and NFκB Signaling

Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML

Suppression of mTOR Signaling Attenuates Apoptotic Effects Induced By the NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Acute Myeloid Leukemia Cells

TAS4464, a Novel, Highly Potent NEDD8-Activating Enzyme Inhibitor Shows Antitumor Activity in Ibrutinib-Insensitive Mantle Cell Lymphoma Via Inactivation of the NF-κB Pathway

TAK-243 Is a Selective UBA1 Inhibitor That Displays Preclinical Activity in Acute Myeloid Leukemia (AML)

First in Human, Phase I/II Trial of the Bruton's Tyrosine Kinase Inhibitor (BTKi) M7583 in Patients with B Cell Malignancies: Study Design and Initial Outcomes

Altered Expression of Neddylation Pathway Proteins in Myelodysplastic Syndromes

The Impact of Autophagy on the Progression of the Myelodysplastic Syndromes

Inhibition of HDAC5-Mediated p65 Deacetylation Enhances Human Cord Blood Hematopoietic Stem Cell Homing and Engraftment in NSG Mice

Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo

The NEDD8 Activating Enzyme Inhibitor Pevonedistat Induces ER Stress/UPR-Mediated Cell Death and Rebalances Homeostasis of Pro- and Anti-Apoptotic Proteins in Favor of Cell Death in Acute Lymphoblastic Leukemia Cells

FAM20c-Mediated Serine 1613 Phosphorylation in the A2 Domain of Von Willebrand Factor Regulates ADAMTS13 Activity and Thrombus Formation

Immunomodulatory Drugs Are Efficacious Against Primary Effusion Lymphoma By Targeting IKZF1, IRF4 and MYC in a CRBN-Dependent Manner and Are Synergistic with BRD4 Inhibitors

Inhibition of Nuclear Factor Kappa B (NFkB)/Interferon Regulatory Factor 4 (IRF4) Signaling Pathway in Activated B-Cell (ABC) Diffuse Large B-Cell Lymphoma (DLBCL) By Combining MLN4924, a Novel NEDD8 Activating Enzyme Inhibitor (NAE) and Ibrutinib

Targeting Microenvironment-Mediated NFκb Activation With MLN4924, An Inhibitor Of The Nedd8-Activating Enzyme, In Chronic Lymphocytic Leukemia B Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only